SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Syndax Pharmaceuticals Inc (SNDX) does not present a strong buy opportunity for a beginner, long-term investor at this moment. The stock lacks significant positive catalysts, has a neutral trading sentiment, and shows a downward probability trend in the short term. Additionally, there are no recent Intellectia Proprietary Trading Signals or congress trading data to support a strong buy decision.
The MACD is positive and expanding, indicating a potential bullish momentum. However, the RSI is neutral at 67.076, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 18.37, with resistance at 19.787 and support at 16.953. Overall, the technical indicators provide mixed signals.
Analysts maintain a Buy rating with price targets ranging from $31 to $46, indicating long-term potential. The company's focus on Revuforj and axatilimab programs shows promise for future growth.
The stock has a 40% chance of declining by -6.41% in the next week and -8.4% in the next month based on historical patterns. Additionally, there are no recent news updates or significant insider or hedge fund activity to drive immediate positive momentum.
No financial data available for the latest quarter. However, analysts have noted revenue misses in recent quarters, particularly for Revuforj, which could weigh on the stock's near-term performance.
Analysts maintain a Buy rating with price targets adjusted slightly downward recently. Guggenheim lowered its target to $31 from $34, UBS to $37 from $38, and Jefferies to $37 from $40. Despite these adjustments, confidence remains in the company's long-term growth trajectory.
